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Attaching and effacing Escherichia coli cause diarrhea and
typically produce lymphostatin (LifA), an inhibitor of mitogen-
activated proliferation of lymphocytes and pro-inflammatory
cytokine synthesis. A near-identical factor (Efa1) has been
reported to mediate adherence of E. coli to epithelial cells. An
amino-terminal region of LifA shares homology with the cata-
lytic domain of the large clostridial toxins, which are retaining
glycosyltransferases with a DXD motif involved in binding of a
metal ion. Understanding themode(s) of action of lymphostatin
has been constrained by difficulties obtaining a stably trans-
formed plasmid expression clone. We constructed a tightly
inducible clone of enteropathogenic E. coli O127:H6 lifA for
affinity purification of lymphostatin. The purified protein in-
hibitedmitogen-activatedproliferationofbovineTlymphocytes in
the femtomolar range. It is a monomer in solution and themolec-
ular envelope was determined using both transmission electron
microscopy and small-angle x-ray scattering.Domain architecture
was further studied by limited proteolysis. The largest proteolytic
fragment containing the putative glycosyltransferase domain was
tested in isolation for activity againstT cells, andwas not sufficient
for activity. Tryptophan fluorescence studies indicated that
lymphostatin binds uridine diphosphate-N-acetylglucosamine
(UDP-GlcNAc) but not UDP-glucose (UDP-Glc). Substitution
of the predictedDXDglycosyltransferasemotif with alanine res-
idues abolished UDP-GlcNAc binding and lymphostatin
activity, althoughother biophysical propertieswereunchanged.
The data indicate that lymphostatin has UDP-sugar binding
potential that is critical for activity, and is a major leap toward
identifying the nature and consequences of modifications of
host cell factors.
Enterohemorrhagic Escherichia coli (EHEC)4 and entero-
pathogenic E. coli (EPEC) are enteric bacterial pathogens of
worldwide importance. Both pathotypes colonize intestinal
mucosa via the formation of “attaching and effacing” lesions in
a manner that requires a Type III protein secretion system, as
well as accessory virulence factors including surface adhesins
(1). Lymphostatin (also known as LifA) is a chromosomally
encoded protein with a predicted molecular mass of 365 kDa
produced by most EPEC and non-O157 EHEC strains (2). We
have previously demonstrated that lymphostatin is required for
intestinal colonization of calves by non-O157 EHEC sero-
groups O5, O111 (3), and O26 (4), and it also promotes coloni-
zation of the murine intestines and colonic hyperplasia by the
attaching and effacing pathogen Citrobacter rodentium (5).
Chlamydia species also contain a family of proteins that have
homology to lymphostatin, and which have been implied to act
as cytotoxins (6).
Lymphostatin was first described as the factor required for
inhibition ofmitogen-activated proliferation of lymphocytes by
enteropathogenic E. coli O127:H6 lysates (2). This activity has
been demonstrated against lymphocytes from peripheral blood
and the intestines (3, 7) and is not associated with direct cyto-
toxicity. Peripheral blood mononuclear cells from mice, cattle,
and humans are sensitive to lymphostatin (2, 3, 5). Lymphosta-
tin has also been reported to inhibit the production of pro-
inflammatory cytokines including IL-2, -4, -5, and interferon-
(7), and it has been suggested that it may therefore interfere
with the induction of innate and adaptive immune responses. In
the same year as LifA was described in EPEC, a near identical
factor was described in EHEC O111:H that was associated
with bacterial adherence to cultured epithelial cells. The
authors named the factor EHEC factor for adherence 1 (Efa1),
however, it has 97.4% amino acid identity to lymphostatin, and
they are likely equivalent proteins (8). Although a direct role of
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Efa1 in adherence has been reported using rabbit EPEC (9),
mutations in some strains impair expression and secretion of
Type III secreted proteins required for attaching and effacing-
lesion formation (3). Furthermore, it has recently also been
reported that lymphostatin can be secreted via the type III
secretion system, but its functions once injected into host cells
are unknown (10).
Understanding of the mode of action of lymphostatin has
been constrained by the instability of plasmid clones and diffi-
culties in obtaining full-length purified protein (2). Further-
more, even plasmid-driven soluble expression of smaller frag-
ments of lymphostatin has proven to be difficult (11).
Bioinformatic analysis has identified homology between the
amino-terminal of LifA/Efa1 and the catalytic glycosyltrans-
ferase domain of the LCTs (2, 8). These clostridial cytotoxic
molecules are large proteins whose catalytic domain glycosy-
lates Rho-family GTPases that regulate the actin network (12).
They are retaining enzymes with a GT-A fold, which belong to
glycosyltransferase family 44 and are characterized by having a
DXD (Asp-Xaa-Asp) motif involved in metal ion binding
together with the diphosphate moiety of the UDP-sugar donor
(13). It is a multistep reaction dependent on the DXD motif,
where sugar binding and hydrolysis is followed by transfer of
the released sugar to an acceptor protein (reviewed in Ref.
12).
In addition, recent studies show that attaching and effacing
E. coli express another novel protein, NleB, which is an effector
glycosyltransferase injected into host cells upon infection. NleB
blocks death receptor-induced apoptosis and promotes intesti-
nal colonization (14, 15), as part of a suite ofE. coli effectors that
influenceNF-B signaling inmammalian cells (reviewed in Ref.
16). NleB uses uridine diphosphate N-acetylglucosamine
(UDP-GlcNAc) as its donor sugar and covalently N-links a
GlcNAc to a conserved arginine residue in death domain con-
taining adaptor proteins (14, 15). This modification had not
previously been described and most GlcNAc addition to pro-
teins occurs viaO-linkage on serine/threonine residues (14, 15).
Apart from the glycosyltransferase domain, searches also iden-
tified a Yersinia YopT-like cysteine protease (CP) motif in the
sequence of lymphostatin (17). These features represent a small
portion of the primary sequence of lymphostatin, and are
restricted to the N-terminal third of the protein. Although one
report claimed that deletion of the predicted glycosyltrans-
ferase and cysteine protease motifs attenuated C. rodentium in
mice (5), close inspection reveals that stop codons were intro-
duced that resulted in protein truncation at the deletion site
rather than in-frame mutations, making the results difficult to
interpret (4). Given its large size and the paucity in understand-
ing how lymphostatin is able to carry out its activities, we
sought to produce a full-length recombinant lymphostatin and
characterize its structural and biophysical features, as well as its
effects on activated T cells. Here we show that full-length lym-
phostatin can be expressed as a folded, biologically active
recombinant protein that inhibits bovine T cell proliferation at
very low concentrations. Furthermore, like other glycosyltrans-
ferases, it has sugar-binding potential, and both its biological
activity and sugar binding is dependent on a DXDmotif, which
has been implicated in the activity of glycosyltransferases.
Although the activity of lymphostatin was identified more than
a decade ago, this is the first significant step forward in under-
standing the mechanisms underlying its intrinsic activities.
Experimental Procedures
Cloning—The full-length gene encoding lymphostatin (9.6
kb) was cloned using the commercially available Expresso
Rhamnose cloning and expression system (Lucigen Inc.) from
the prototype enteropathogenicE. coli serotypeO127:H6 strain
E2348/69. The lymphostatin gene was amplified using genomic
DNA from E2348/69 as lymphostatin activity was first de-
scribed in this strain (2). The pRham vector incorporates a
C-terminal in-frame His6 tag. Amplicons were generated using
the primers EXPLifA_FOR, 5-GAAGGAGATATACATATG-
AGACTGCCAGAGAAAGTTCTT-3 and EXPLifA_REV, 5-
GTGATGGTGGTGATGATGGTTAAAAAGGTTGTCACC-
ATT-3 with PHUSION proofreading polymerase (Thermo
Scientific). Amplicons of the appropriate size were isolated by
agarose gel electrophoresis and purified using Geneclean II
(MP Biomedicals, Inc.). The amplicons were cloned into pre-
linearized pRham vector by homologous recombination in
E. cloni 10G (Lucigen Inc.) chemically competent cells. Sub-
sequent transformants were screened by colony PCR using
primers supplied by the manufacturer: pRham Forward, 5-
GCTTTTTAGACTGGTCGTAGGGAG-3 and pETite Re-
verse, 5-CTCAAGACCCGTTTAGAGGC-3. The sequence of
two independent clones (pRHAM-LifA-6xH) were confirmed
to be identical to the published lifA sequence of E2348/69 (gene
E2348C_3234; (18)) by full-length Sanger sequencing on both
strands using primers every 500 bp (GATC-Biotech).
Generation of a DTD to AAA Lymphostatin Substitution
Mutant—To remove the DXD motif the amino acids DTD at
position 557–559 were substituted with AAA using the
QuikChange II XL site-directedmutagenesis kit (Agilent Tech-
nologies) according to the manufacturer’s directions. Briefly,
using the pRHAM-LifA-6xHplasmid as a template, the primers
LifA-DXD-1 (Forward), GGATGTATATCCTTAAAGAGCA-
TGGTGGTATTTATACAGCGGCCGCGATGATGCCTGC-
ATACTCTAAACAAGTAATTTTTAAAA, and LifA-DXD-2
(Reverse), TTTTAAAAATTACTTGTTTAGAGTATGCAG-
GCATCATCGCGGCCGCTGTATAAATACCACCATGCT-
CTTTAAGGATATACATCC, were used to introduce AAA to
the sequence, by total replication of the plasmid, followed by
digestion of the parent plasmid. A NotI restriction endonu-
clease site (indicated in bold) was also introduced at the site of
mutation. Putative mutant plasmids were screened by restric-
tion digest with NotI, and verified by Sanger sequencing on
both strands (GATC-Biotech).
Recombinant Lymphostatin Expression and Purification—
Recombinant His-tagged lymphostatin (rLifA) was overex-
pressed in E. cloni cells cultured in lysogeny broth at 37 °C,
250 rpm shaking to A600 nm 0.8. Expression of the protein was
induced by the addition of L-rhamnose to 0.2% (w/v) and cul-
tured for a further 3 h at 30 °C. Cells were pelleted by centrifu-
gation, re-suspended in 20 mM sodium phosphate (NaH2PO4),
pH 7.6, 300 mM sodium chloride, 500 mM non-detergent sulfo-
betaine (NDSB201), 20 mM imidazole, 5% (v/v) glycerol, 1 mM
dithiothreitol (DTT), 100 M phenylmethylsulfonyl fluoride, 1
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complete protease inhibitor tablet/3 g cell mass (Roche), 0.1%
(v/v) Tween 20 and lysed by high pressure lysis by single pas-
sage, at 30 kpsi, through a Constant Systems TS 1.1 kWBench-
top Cell disruptor. All chromatography was performed on an
ÄKTA Explorer 10 UV900 LC system (GE Healthcare) at 6 °C.
The lysate was clarified by centrifugation (50,000  g at 4 °C)
and loaded onto a Ni2 ion-metal affinity chromatography
(IMAC) column (HisTrap FF; GE Healthcare) pre-equilibrated
in 20 mM sodium phosphate, pH 7.6, 300 mM sodium chloride,
20 mM imidazole, 5% (v/v) glycerol, 1 mM DTT, 0.1% (v/v)
Tween 20 at 2 ml/min. This was followed by washing with 15
column volumes (cv) of the same buffer (Buffer A) and 15 cv of
Buffer A supplemented with 4% Buffer B (20 mM sodium phos-
phate, pH 7.6, 300 mM sodium chloride, 500 mM imidazole, 5%
(v/v) glycerol, 1 mM DTT, 0.1% (v/v) Tween 20). rLifA was
eluted by increasing the concentration of imidazole up to 500
mM over 5 cv (gradient over 5 cv); all at 2 ml/min. rLifA was
passed over a size exclusion column pre-equilibrated in 20 mM
sodium phosphate, pH 7.6, 300 mM sodium chloride, 5% (v/v)
glycerol, 1 mM DTT, 0.1% (v/v) Tween 20 to separate low
molecular weight contaminants (Superose-6pg XK16/60; GE
Healthcare) at 1 ml/min. Fractions containing rLifA were
buffer exchanged into 15mM sodiumphosphate, pH 7.6, 50mM
sodium chloride, 5% (v/v) glycerol, 1 mM DTT, 0.05% (v/v)
Tween 20 at 8 ml/min and further purified to homogeneity by
anion exchange (HiPrep desalt 26/10; Mono-Q 5/50 GL; GE
Healthcare) at 1 ml/min. The protein was eluted by running a
gradient from 15 to 500mMNaCl over 30 cv; the protein eluted
at a salt concentration of 160mM. AAAmutant full-length lym-
phostatin (rLifADTD/AAA) was purified using the same strategy
as rLifA protein, and the chromatograms were indistinguish-
able. The induction, size, and stability of expressed proteins
were assessed by 3–8% Tris acetate SDS-PAGE and/or by
Western blotting with monoclonal antibody specific for His6
(4A12E4, Novex, Life Technologies) according to the manufa-
cturer’s instructions (Novagen).
Isolation of Peripheral Blood Mononuclear Cells (PBMCs)
and T Cells from Bovine Blood—Access to bovine blood for
these studies was approved by the local ethics committee and
blood draws were carried out in accordance with the Animals
(Scientific Procedures) Act 1986. PBMCs were isolated from
12–18-month-old Holstein-Friesian cows. Briefly, blood was
collected into heparinized bags or syringes. Following centrifu-
gation at 1,200 g for 15 min to generate an initial buffy coat,
the white blood cell fractions were pooled, layered over Ficoll-
Paque Plus (GE Healthcare), and centrifuged for 30 min at
1,200  g with the brake off. The PBMCs were collected from
the interface and washed several times before use. If required,
the T lymphocyte fraction was further enriched using a sterile
wool column (Polysciences, Inc.), as suggested by themanufac-
turer. Briefly, columns were washed in sterile Roswell Park
Memorial Institute medium (RPMI) supplemented with 10%
(v/v) fetal bovine serum, 20 mMHepes, 1 mM sodium pyruvate,
100 units/ml of penicillin/streptomycin, 20 mM L-glutamine
(Life Technologies), and incubated for 1 h at 37 °C in a 5% CO2
atmosphere. Cells were applied at 108/ml, run into the column
by gravity, and incubated for 1 h at 37 °C per 5%CO2. Unbound
cells (mainly composed of T cells) were washed off the column
in 10 ml of medium, spun down, and counted. The purity of T
cell preparationswas checked by single channel flow cytometry.
Cells were stained with a commercially available anti-bovine
CD3 antibody (MM1A; IgG1; VMRD, Pullman, WA). Second-
ary staining with a FITC-conjugated anti-IgG1 secondary anti-
body was carried out, and the samples were analyzed on a
FACSCalibur using CellQuest (BD Biosciences) and FloJo soft-
ware (Tree Star). A minimum of 10,000 events were collected,
with an initial gate for live cells based on forward/side scatter
parameters.
Proliferation Assay—Enriched T cells were used to test the
activity of rLifA, purified partial fragments, and rLifADTD/AAA
using a standard colorimetric measurement of mitogenic acti-
vation of proliferation. Cells were plated at 2 105 cells/well in
96-well flat-bottom plates (Costar) in triplicate for all condi-
tions. rLifA, rLifADTD/AAA, or a fragment thereof was added at
a final concentration as indicated in the figure legends. Cell
proliferation was stimulated using the mitogen concanavalin A
(ConA, Sigma) at a final concentration of 1 g/ml in the pres-
ence or absence of recombinant lymphostatin as indicated in a
final volume of 100 l/well. Cells were incubated at 37 °C for
72 h. The colorimetric substrate CellTiter 96 AQueous One
(Promega) was added 18 h before the end of the assay. All mea-
surements were carried out at 492 nm on a Multiskan Ascent
plate reader (Thermo Scientific). Cells and medium alone were
used as negative controls. Background medium measurements
were subtracted from all values. All treatments are expressed as
a Proliferation Index, which is calculated by the ratio of: [absor-
bance(cellstreatedwithConAandrecombinantprotein)/absor-
bance (cells treated with ConA alone)]. Isolated T cells were
tested for cytotoxic effect of rLifA using a lactate dehydroge-
nase release assay (Cytotoxicity Detection Test Plus, Roche)
according to the manufacturer’s directions, using an 8-h incu-
bation period.
Limited Proteolysis and MALDI Mass Spectrometry—The
identity of full-length recombinant lymphostatin was con-
firmed by in-gel protein digest and peptide analysis. Excised
gel-bands were incubated at a porcine trypsin:lymphostatin
ratio of 1:30, in 50 mM ammonium bicarbonate overnight at
32 °C (Promega). Peptides were identified by matrix-assisted
laser desorption ionization (MALDI) mass spectroscopy on a
Voyager DE-STR MALDI-TOF mass spectrometer (Applied
Biosystems) using an -cyano-4-hydroxycinnamic acid matrix.
The spectral data were processed using Data Explorer software
(Applied Biosystems) and the MASCOT NCBInr database
searched against the peptide mass map (Matrix Science). To
investigate the domain structure of lymphostatin, purified pro-
tein was incubated with trypsin at a ratio of 375:1, at 21 °C, to
give limited digestion. Aliquots were removed at 1, 2, 3, and 4 h
and the reaction stopped by boiling samples adjustedwith 2mM
EDTA and 2 mM PMSF in SDS-PAGE loading buffer. Digest
products were separated by SDS-PAGE and individual bands
were subjected to in-gel tryptic digestion and MALDI-TOF
mass spectroscopy as described above. Peptide masses were
compared with the sequence of full-length rLifA using
GPMAW 9.2 software, mass tolerance 50 ppm (19). Fragment
F1 was purified to homogeneity from other digest products by
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ion-exchange chromatography (Mono-Q 5/50 GL; GE Health-
care) as described above.
Size Exclusion Chromatography-Multi-angled Light Scatter-
ing (SEC-MALS)—Size exclusion chromatography coupled to
UV, static light scattering, and refractive index detection were
used to determine the molecular mass of pure rLifA in solution
and to estimate the detergent load (Viscotec SEC-MALS 20 and
Viscotek RI Detector:VE3580; Malvern Instruments). One
hundred l of 1 mg/ml of lymphostatin was passed over a size
exclusion column pre-equilibrated in 20 mM sodium phos-
phate, pH 7.6, 150 mM sodium chloride, 1 mM DTT, 0.1%
Tween 20 (Superose6 10/300 GL, GE Healthcare) at 24 °C.
Light scattering, refractive index (RI), and A280 nm were ana-
lyzed by a conjugate protein model using the following param-
eters: A280 nm for lymphostatin and Tween 20 detergent, 0.97
and 0.01 absorbance unit, ml/mg, respectively; RI for protein,
0.187 ml/g; and Tween 20, 0.145 ml/g (Malvern Instrument
software).
Circular Dichroism (CD)—The far UV CD spectrum of full-
length lymphostatin (0.11 M), rLifADTD/AAA (0.11 M), and
the digest fragment F1 (0.35 M) were recorded at 10 nm/min;
data pitch, 0.1 nm; response time, 2 s between 185 and 285 nm
in a 0.1-cm path length quartz cuvette at 25 °C (JASCO-810
spectrometer). The proteins were exchanged into 10 mM
sodium phosphate, pH 7.6, 150 mM sodium fluoride prior to
analysis (HiTrap desalt column, GE) at 4 ml/min. Spectra were
corrected by subtracting a buffer baseline, each an average
of 5 spectra. Secondary structure was estimated using the
Dichroweb CD secondary structure analysis server (20) includ-
ing the methods CONTIN, SELCON3, and CDSSTR (21–24)
and reference data sets SP175 and 7 (25).
Bioinformatic Analysis—The secondary structure of lym-
phostatin was predicted from sequence using PredictProtein
(26) and PSIPRED (27). Proteins with similar structural ele-
ments and homologues were identified with PHYRE (28) and
BLASTp (29).
Intrinsic Tryptophan Fluorescence—Binding of uridine
diphosphate-glucose (UDP-Glc) and UDP-GlcNAc to wild-
type LifA and LifADTD/AAA was determined by ligand-induced
changes in intrinsic tryptophan fluorescence. Fluorescence
measurements were performed on a SPEX Fluoromax 3 spec-
trometer (Horiba) in a 3-ml stirred cuvette by titrating the
UDP-sugar into 0.2 M lymphostatin at 20 °C in 20 mM sodium
phosphate, pH 7.6, 150 mM sodium chloride, 5% glycerol, 0.1%
Tween 20, 1 mM DTT. Samples were allowed to equilibrate for
5min after the addition of each aliquot. The final volume added
did not exceed 2%of the initial volume. Tryptophanwas excited
at 295 nm and emission spectra were recorded from 310 to 400
nm, with a 1-nm interval. Excitation and emission slits were set
at 5 nm, with an integration time of 1 s. The equilibrium disso-
ciation constant was obtained from fitting the fluorescence
intensity at 340 nm to a binding model corrected for collisional
quenching (Kaleidagraph, Synergy Software).
Negative Staining and Electron Microscopy—Four hundred
mesh carbon-coated copper grids were glow discharged for 1
min in a Quorum Tech sputter coater with a current of 25 A
andusedwithin 1 h. rLifA (4l at8g/ml concentration)was
applied to a glow discharged grid and incubated for 1–2 min.
Next, the grid was washed with 2 drops of water and 2 drops of
2% uranyl acetate followed by stainingwith a further drop of 2%
uranyl acetate for 4–5 min. Finally, excess liquid was blotted
from the edge of the grid with filter paper (Whatman No. 5).
Dried grids were imaged with an FEI F20 field emission gun
electron microscope equipped with an 8k x 8k TVIPS CMOS
camera (F816). The camera format was binned by a factor of 2
giving a calibrated binned pixel size of 3.06 Å/pixel at the spec-
imen level. Micrographs were acquired semi-automatically
with EM-tools (TVIPS GmbH) under low dose conditions (20
e/Å2, at 200 kV).
EM Image Processing—The defocus of each micrograph was
determined with ctffind3 (30). Particles were selected semi-au-
tomatically using e2boxer (31). Selected particle images were
extracted and normalized with RELION (32), with a box size of
128 pixels. The radius for background normalization was 55
pixels. Extracted particle images were classified into 100 two-
dimensional classes using RELION. Particle images, which did
not align with an accuracy of better than 4 degrees in the two-
dimensional classification were excluded from further pro-
cessing. This reduced the number of particle images in the data
set from 27,431 to 25,244. The relative spatial orientations of
two-dimensional class averages of the remaining particle
images were determined by sinogram correlation in IMAGIC
(33). After determining the relative orientations of the class
averages a three-dimensional map was calculated by weighted
back projection. The orientations of the class averages were
further refined by angular reconstitution using projections of
the three-dimensional map as anchor set followed by calculat-
ing an improved three-dimensional map by back-projection.
The resulting three-dimensional map was used as reference in
Relion for autorefinement of the data set. The resolution was
estimated by Fourier-Shell correlation between two indepen-
dently processed data sets (34) and was 23 Å at a Fourier-Shell
correlation of 0.14 (35). The absolute hand of the map is
unknown.
Small-angle X-ray Scattering (SAXS)—Synchrotron radia-
tion data were collected at the I911-4 SAXS beamline at the
MAX-II Laboratory (Lund, Sweden) as 4 30-s exposures of a
20–30-l sample and scattering profiles were compared with
detect radiation damage. Lymphostatin was buffer exchanged
into 20 mM NaH2PO4, pH 7.6, 300 mM NaCl2, 2 mM DTT, and
5% (v/v) glycerol (an identical buffer to the size-exclusion stor-
age buffer but without Tween 20) prior to SAXSmeasurements
using Amicon Ultra 0.5-ml centrifugal filters (Merck). Data
were collected at 0.91-Å wavelength at 10 °C with a Dectis
hybrid pixel Pilatus 1M detector. To detect concentration-de-
pendent inter-particle effects, measurements were collected at
multiple protein concentrations in the range of 0.67–1.6
mg/ml, and the 1 mg/ml scattering curve was used for all sub-
sequent analysis. Background buffer scattering was subtracted
using PRIMUS (36), part of the ATSAS package (37). Pair dis-
tance distribution function P(r) and the maximum particle
dimensionDmax were computed using GNOM (38). The Porod
volume was calculated using ATSAS AUTOPOROD (39) and
used for molecular weight estimation.Ab initio shape envelope
was developed using 10 independent DAMMIF (40) computa-
tions in P1 symmetry. DAMAVER (41) was used to align and
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compare the resulting models. The most representative model
was subsequently refined using DAMMIN (42). The resulting
bead model was used to compute a surface envelope with Situs
pdb2vol (43). The DAMMINmodel was manually aligned with
the EM density map using USCF Chimera (44).
Statistical Analysis of ED50 of rLifA and rLifADTD/AAA—The
effective dose 50 (ED50) for rLifA and rLifADTD/AAA was deter-
mined using drc in R (45). One way analysis of variance was
used to determine statistically significant differences between
both ED50 and dose-response curves usingMinitab (46), with p
values 0.05 taken to be significant. Post hoc Tukey test was
used to calculate 95% confidence intervals and confirm signifi-
cance (46).
Results
Full-length Lymphostatin Can Be Produced as a Stable,
Tagged Recombinant Protein—Published studies have noted
instability of lymphostatin clones (2, 47) or inability to assemble
the full-length gene from amplicons (8), possibly because of
toxicity and gene size. To overcome this, an amplicon of the
EPEC O127:H6 E2348/69 full-length lifA gene (9.6 kb) was
cloned in pRham with a carboxyl-terminal histidine tag. In this
Expresso Rhamnose cloning system, tight control of expression
was achieved using a combination of glucose to repress tran-
scription from the rhamnose-inducible promoter and a 3-h
induction with 0.2% (v/v) L-rhamnose. Purification was opti-
mized as described under “Experimental Procedures,” and Fig.
1, A–C, illustrates the steps in the purification strategy. No
evidence of lymphostatin production was detected in unin-
duced cultures of E. coli harboring sequence-verified lifA, how-
ever, L-rhamnose induction led to the expression of rLifA, as
detected by Coomassie staining and Western blotting with an
anti-His tag antibody (Fig. 1C, inset).
To confirm that the expressed protein is full-length lym-
phostatin, in-gel tryptic digestion and MALDI mass spectrom-
etry were carried out. The resulting peptides aligned to 41% of
the lymphostatin primary sequence, from residue 52 to 3174 (of
3229); representing good coverage for such a large protein. The
predicted N terminus of the protein is relatively rich in basic
residues. Lack of tryptic peptide coverage at the N terminus
could be accounted for by extensive digestion at charged resi-
dues generating many low mass fragments that are not detect-
able byMALDI. TheC-terminal end can be inferred to be intact
because of detection of the histidine tag and by IMAC purifica-
tion and Western blotting. The purified protein was analyzed
by dynamic light scattering. The sample contained species with
a Stokes radius of 6.5 nm, consistent with monomeric rLifA.
There was no evidence of aggregation or insolubility (data not
shown).
rLifA Is Biologically Active against Bovine TCells—Lymphos-
tatin-containing bacterial lysates have been reported to be
FIGURE 1.Multiple-step purification of rLifA yields highly pure, full-length monomeric protein. A, ion metal affinity chromatography (HiTrap IMAC FF)
elutionprofile; lymphostatin (L)waselutedover a4–100%gradientof Buffer B.B, sizeexclusionchromatography separated lymphostatin from lowermolecular
weight contaminants from the expression system (Superose 6pg XK16/60). C, ion exchange chromatography (Mono-Q 5/50 GL) was used as a final polishing
step; full-length lymphostatin eluted at 160mMNaCl. Inset, Coomassie-stained gel of 0.5g of purified full-length lymphostatin (left lane), Western blot of 0.1
g of purified full-length lymphostatin probed with anti-His6 antibody (right lane). D, SEC-MALS chromatogram of purified lymphostatin (Superose 6 10/300
GL): A280 nm (solid line) and refractive index trace (dashed line). Lymphostatin eluted at 14.5 ml and has an estimated mass of 330 15 kDa; detergent micelle
eluted separately with an estimated mass of 76 5 kDa (thick black trace).
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capable of inhibiting the proliferation of mitogen-stimulated
PBMCs using cells from humans, mice (2, 7), and cattle (3, 11).
Using an enriched bovine T cell population increased the sig-
nal-to-noise ratio compared with use of bulk PBMCs, giving a
wider dynamic range to the assay. Using T cells obtained from
four independent donors, purified rLifA inhibited ConA-stim-
ulated proliferation, showing inhibition from the low femtomo-
lar range with concentration-dependent titration of activity
with a sigmoidal curve (Fig. 2). Measurements of the ConA-
stimulated response were typically 2–5-fold higher than cells
alone. The carrier buffer for rLifA was determined to have no
effect on ConA stimulation of cells on its own. Furthermore, a
colorimetric assay to detect release of cytosolic lactate dehydro-
genase foundno evidence of cell lysis when primaryT cells were
treated with inhibitory concentrations of rLifA, indicating that
the inhibitory effect of lymphostatin on T cells is unlikely to be
a consequence of direct cytotoxicity.
Lymphostatin Is aMonomer in Solution—Having established
that rLifA is biologically active, we examined its structural char-
acteristics. SEC-MALS was used to calculate the average
molecular weight of rLifA in solution and hence the oligomeric
assembly. Lymphostatin eluted as a well resolved single peak.
Light scattering, RI, and UV were analyzed by a conjugate pro-
tein model, and the mass of lymphostatin was predicted to be
330 15 kDa, slightly lower than the predictedmolecularmass
formonomeric protein of 365 kDa (Fig. 1D). Given themapping
of the N-terminal to at least 52 residues from the beginning of
the putative start of the protein, and that the C-terminal is
intact, the size differential to the calculated size is unlikely to be
due to truncated protein, and is within acceptable error for the
technique at the present time, taking into account the glycerol
and detergent-rich buffer. Detergent micelle eluted later than
protein with an estimated mass of 76 5 kDa (Fig. 1D). Taken
together the data indicate that lymphostatin is a monomer in
solution and that it is not necessary for the protein to fully or
partially be enclosed within a micelle to remain in solution.
Limited Proteolysis Identified 3 Putative Structural Do-
mains—With no fine structural information available on lym-
phostatin we set out to predict putative physical domains using
limited proteolysis; the premise being that loops and flexible
regions of the protein are more susceptible to digestion than
buried residues. Limited tryptic proteolysis of rLifA over sev-
eral hours revealed a defined and consistent pattern of cleavage
products. Five major fragments were identified by mass spec-
trometry, F1-F5 (Fig. 3A). Mass spectrometry of tryptic pep-
tides from each species and alignment of peptides against/with
the lymphostatin primary sequence suggested 3 major do-
mains, with the additional two species representing truncated
versions of two of the major digestion products, as indicated in
Fig. 3B. Identification of peptides by MALDI-TOF mass spec-
trometry from the in-gel tryptic digestion of fragments initially
generated by limited proteolysis does not precisely identify pro-
tein domain boundaries but may be considered a useful guide.
Limited proteolysis fragments are likely to be somewhat longer
at both the N and C terminus than the most N-terminal and
C-terminal residues identified from their tryptic digestion and
MS analysis. The largest intact fragment, designated F1, repre-
sents a 1435 amino acid (aa) region at the N terminus of
FIGURE 2. Concentration-dependent inhibition of T cell proliferation by
full-length rLifA. Effect of concentrationof lymphostatin against ConA-stim-
ulated peripheral bovine T cells. Data shown are the average of 4 indepen-
dent donors, done in triplicate. Error bars indicate S.E. The purity of the cells
usedwas85% in each experiment, asmeasured by CD3 staining using flow
cytometry. Calculated ED50 was 25 4.6 pg/ml (68 fM); 100 ng/ml is equiva-
lent to273 pM. Concentrations on the x axis are displayed on a log scale.
FIGURE 3. Domain organization of lymphostatin. A, limited proteolysis of lymphostatin gave a consistent digest pattern. Five fragments, F1–F5, were
identified by mass spectrometry. B, analysis of the primary amino acid sequence of lymphostatin predicts a glycosyltransferase (GT) and cysteine-type
endopeptidase domain (CP). Black bar illustrates full-length protein (FL). Fragment F1 contains the putative GT and CP domains. Fragment F2 maps more
closely to the GT domain with a C-terminal extension of140 aa.
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lymphostatin, starting about 177 aa from the N terminus, and
encompassing both the putative glycosyltransferase (GT) and
cysteine protease (CP) motifs. The two smaller fragments are
separated from the N-terminal fragment by about 500 aa, and
are approximately776 aa (F3) and 271 aa (F5), respectively. In
addition, the two C-terminal proximal fragments are separated
by a short stretch of 43 aa. Residues 1600–2100 are not repre-
sented in the major early digest products but were very well
represented in the full tryptic digest during mass spectrometry
analysis, suggesting this region is intact in the full-length pro-
tein. The abundance of fragment F1 reduces as the digest
time increases, whereas fragment F2, an N and C terminally
truncated subfragment of F1, becomes relatively more abun-
dant. Fragment F2 maps more closely to the GT domain with
a C-terminal extension of140 aa. The N-terminal100 aa
of F1 is richer in basic amino acids than the full-length lym-
phostatin. This property enabled us to separate F1 from
other digest products by anion exchange chromatography.
The Predicted Glycosyltransferase Domain of Lympho-
statin—To identify the boundaries of the glycosyltransferase
domain of lymphostatin we performed BLAST analysis of the
primary sequence. We identified homology with the N termini
of LCTs (the first 541 amino acids of TcdA) encompassing their
catalytic glycosyltransferase domains. The alignment indicates
that the sequence of lymphostatin is most similar to that of the
LCTs for residues that define the binding site of the glycosyl
donor substrate, often described at the catalytic core of the GT
domain (Fig. 4A, gray shading) (13). The catalytic core residues
of the LCTs are not contiguous and have insertions that form
helical bundles surrounding the core (Fig. 4B, Toxin A, orange
highlights). These are thought to confer specificity for the pro-
tein that becomes glycosylated by the glycosyltransferase. The
most striking differences in sequences in the LCT GT domains
are within these insertions. To further examine the potential of
lymphostatin to form aGT fold we generated amodel using the
PHYRE2 server (49). The best scoring model is based on Toxin
A from Clostridium difficile, which forms a GT-A-fold com-
mon to all LCTs (Fig. 4C; model of lymphostatin Ala242-
Arg769). Lymphostatin has similar insertions that are predicted
from the sequence to be coiled and helical in character. It is
worth noting that differences to the helical bundles mean that
even if an alignment is restricted to the catalytic core of the
clostridial toxins (residues Thr105-Trp534 in TcdA, which align
to residues Thr309-Phe860 in lymphostatin) the sequence iden-
tity is only 20%, a figure that belies their common features.
Lymphostatin displays good conservation for residues that
make key non-covalent interactions with the UDP-sugar (Fig.
4A, stars above sequence; bold typeface marks identity). The
LCTs and lymphostatin contain the signature DXDmotif, seen
inmost GT domains, through which the aspartate carboxylates
coordinate a divalent cation and the donor substrate (Fig. 4A,
red box). Three residues at the base of the-hairpin in the sugar
donor binding site,XNX, are thought to confer sugar specificity
(Figs. 4A, black box, and 5,A andC). Toxins A, B, and L all have
INQ in this position; this means that the enzymes can accom-
modate UDP-Glc but not UDP-GlcNAc. -Toxin and TpeL bind
UDP-GlcNac; to accommodate the acetyl group, INQ is
replaced by SNAandANQ, respectively. Lymphostatin has leu-
cine in position 1 and glycine in position 3, LNG. Our model
suggests this would make it possible for UDP-GlcNAc to bind
(Fig. 5B).
Given that digest fragment F1 spans both the putative glyco-
syltransferase motif as well as the cysteine protease motif; we
set out to test the F1 fragment in isolation in the bovine T cell
proliferation assay, to explore whether it retained its inhibitory
activity against lymphocytes. Using equimolar amounts of pro-
tein in the ConA-stimulated T cell proliferation assay, compar-
ison of the full-length protein alongside purified F1 revealed
that the F1 fragment was insufficient to inhibit T cell prolifer-
ation in isolation (Fig. 6). This may be because the F1 fragment
N-terminal boundary is at 177 aa and the N-terminal amino
acids are important for interaction with the target protein.
More likely is that the C-terminal domains are crucial for cell
binding and uptake, as has been shown for the large clostridial
toxins (50).
Lymphostatin Is an Ordered Protein with a High -Helical
Content in the Putative Glycosyltransferase Domain—To con-
firm that rLifA was folded and to estimate the content of sec-
ondary structural elements we measured the CD spectrum of
full-length and the F1 fragment that encompasses the putative
GT and the CP domains. The CD spectrum of full-length pro-
tein was consistent with a folded protein and indicated 37%
-helix and 17% -sheet (Fig. 7, A and B); very similar to
PSIPREDpredictions (35%-helical and22%-sheet). The
N-terminal half of the protein was predicted to contain the
majority of the -helical content, whereas the C-terminal third
of the protein was predicted to be rich in -sheet (Fig. 7C). The
samples showed no evidence of aggregation by dynamic light
scattering (ZetasizerAPS, Malvern).
Given the lack of activity of the isolated F1 fragment in the T
cell proliferation assay, and to rule out that the protein was
degraded and/or not folded, CD analysis was carried out on
purified F1 protein. Furthermore, given its location at the
N-terminal part of lymphostatin, where the primary sequence
is predicted to have a higher percentage of -helices, it is
expected that the percentage of -helical content of F1 would
be higher than that of the full-length protein. The F1 fragment
was predicted by PSIPRED to consist of 52% -helical content
and analysis of CD data inferred 51%-helical content. The CD
data is broadly in agreement with the secondary structure pre-
diction for F1 but suggested a slightly higher proportion of
-sheet, 13% as opposed to 5%.
Three-dimensional Shape of Lymphostatin—Negatively
stained rLifA showed a homogeneous distribution of elongated,
slightly kinked particles (Fig. 8). From images of 25,000 of
these particles, we determined a three-dimensionalmapof lym-
phostatin at 23-Å resolution. The map shows an elongated,
L-shaped molecule (Fig. 8). The arms of the “L” are 130–140 Å
long and between 60 and 90 Å thick. To further investigate the
structure of lymphostatin, we also performed SAXS (51, 52).
The linearity of the Guinier region confirms the absence of
inter-particle effects (Fig. 9A). The longest particle dimension
Dmax is 218 Å, which is not dissimilar to the longest dimension
of the EMmap (197Å) (Fig. 9B). The Porod volume (645 nm3)
indicates a particle molecular mass of 358 kDa further suggest-
ing that lymphostatin (365 kDa based on primary sequence)
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behaves as a monomer in solution, and that the recombinantly
purified full-length protein is stable. Next, we determined the
ab initio shape analysis with DAMMIF (40) using 10 indepen-
dent computations producing models related with an average
normalized spatial discrepancy of 0.793. The representative
and DAMMIN (42) refined model shows an elongated L-
shape with dimensions (218 116 100Å) slightly larger than
the EM density map (197 110 89 Å). The alignment of the
EM density map with the SAXS envelope highlights the simi-
larities in dimensions as well as shape (Fig. 9C). The kink of the
L-shaped molecule is situated in a similar position in the two
envelopes, at roughly half the length of the particle, however,
the kink is more defined in the EM map. In addition, the EM
map contains a larger volume within one of the arms of the L.
Lymphostatin Binds UDP-N-acetylglucosamine—Lymphos-
tatin contains 37 tryptophan residues, of which 7 are found
within the putative GT domain; Trp320, Trp534, and Trp863
most likely are in close proximity to the active site (Fig. 4).
Titration of lymphostatin with UDP-Glc gave a linear Stern-
Volmer plot that would be consistent with collisional quench-
ing of solvent-exposed tryptophan rather than any specific
interaction of sugar with lymphostatin (Fig. 10). In contrast
UDP-GlcNAc enhances fluorescence in a non-linear con-
centration-dependentmanner at lower concentrations; there is
FIGURE 4. The putative glycosyltransferase domain of lymphostatin. A, alignment of sequence representing the putative GT domain of lymphostatin with
those of Toxin A and B from C. difficile, Toxin L from Clostridium sordellii, and-toxin from Clostridiumnovyi. Sequenceswere aligned using the programClustal
Omega (66). Red bars represent -helical regions and blue arrows represent -sheet from the crystallographic analysis of Toxin A from C. difficile (Protein Data
Bankcode4DMW(53)). Aminoacid identitiesbetween theLCTsand lymphostatin are indicated inbold. Residues thatmakekey interactionswith theUDP-sugar
in the LCTs are indicated with stars. The core catalytic fold that defines the UDP-Glc donor substrate binding site of the LCTs is indicated with gray shading in
both the sequence alignment and structural representations. The numbering scheme refers to lymphostatin. F2 indicated the N-terminal boundary of digest
fragment F2. B, representation of the crystal structure of toxin A from C. difficile bound to UDP-Glc (Protein Data Bank code 4DMW) (67). C, PHYRE2 (49)
generatedmodel of the GT domain of lymphostatin based on Toxin A from C. difficile. UDP-Glc extracted from Protein Data Bank code 4DMWwasmodified to
UDP-GlcNac and fitted into the putative binding site using Coot (48).
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evidence of collisional quenching at higher concentrations.
This may be explained by UDP-GlcNAc binding in the GT cat-
alytic site and changing the environment of one or more tryp-
tophan residues. At high concentrations of UDP-GlcNAc after
the active site has become saturated there is a linear relation-
ship between fluorescence and UDP-GlcNAc concentration
that could be attributed to collisional quenching of tryptophan
outside the binding site. We have fitted a mixed binding model
to the UDP-GlcNAc data that takes into account specific bind-
ing and collisional quenching. The affinity of lymphostatin for
UDP-GlcNAc is estimated to be 120 30 M. The protein was
expressed in the presence of a variety of divalent cations includ-
ing Ca2, Mg2, and Mn2 that were present in the growth
media. Good reproducibility of affinity data between batches
was achieved by incubating the protein sample with 50 M
MnCl2 after purification. Manganese was selected as the diva-
lent cation based on thermal shift experiments (differential
scanning fluorimetry) that suggested MnCl2 enhanced the
thermal stability of lymphostatin and the additional stabilizing
effect of UDP-GlcNac to a greater extent than MgCl2 (data not
presented) (53). TheKm of full-length TcdA fromC. difficile for
UDP-Glc in the presence of Mg2 is 142 M and has a Kd of
45  10 M (54). The Km for the TcdA-GT domain has been
reported as 36.3 3.6 M and Kd of 11.4 0.9 M (53). Km of
full-length TcdB from C. difficile for UDP-Glc in the presence
of Mg2 is 154 M (55).
The DTD Motif within the GT Domain of Lymphostatin Is
Important in Sugar Binding and Activity against Bovine Lym-
phocytes—Given that the DXD motif has been implicated in
glycosyltransferase activity in other similar molecules (re-
viewed in Ref. 13), we examined the effect of a DTD to AAA
substitution at position 557–559 on both sugar binding and
activity of lymphostatin. rLifADTD/AAA behaved similarly to
rLifA, both during expression and purification, as well as in CD
and DLS lending confidence that the residue substitutions had
not disrupted the original structure of the protein.
Testing rLifADTD/AAA using the tryptophan fluorescence
assay and titrating eitherUDP-Glc orUDP-GlcNAc as for rLifA
gave linear Stern-Volmer plots indicative of nonspecific
quenching and lack of sugar binding (Fig. 11A). Furthermore,
titration of the rLifADTD/AAA protein in the bovine T cell pro-
liferation assay shows a drastic reduction in its ability to inhibit
proliferation by almost 4 orders of magnitude (ED50 rLifA 	
0.014 ng/ml 0.0015, rLifADTD/AAA	 922 ng/ml 270) (Fig.
11B). These two observations imply that not only is the DTD
motif important for sugar binding, but is also critical for the
inhibitory activity of lymphostatin on T cells.
Discussion
Lymphostatin plays an important role in intestinal coloniza-
tion by attaching and effacing E. coli and is therefore a poten-
tially attractive target for intervention. Although functions
have been assigned to this large molecule, its mode of action
remains largely unknown. It is one of relatively few bacterial
molecules reported to interfere with the function of adaptive
immune cells. Historically, it has proven difficult to obtain a
stable clone to express and purify full-length lymphostatin (2, 8,
47). Using a tightly inducible prokaryotic expression systemwe
were able to express and purify lymphostatin with potent activ-
ity againstmitogen-stimulatedT lymphocytes.Mass spectrom-
etry of tryptic peptides and SAXS indicate that the purified
full-length protein is stable. Lymphostatin contains predicted
non-canonical prepilin peptidase sites (8), however, it is not
clear whether it is processed, at least in the laboratory-adapted
E. coli K-12 strain used for expression, nor is there a predicted
signal sequence at the N terminus.
Since its discovery, two predicted features have been known
in lymphostatin: namely a glycosyltransferase domain and a
YopT-like cysteine protease domain (8, 17). Although both
motifs were implicated in colonization of mice and colonic
hyperplasia by C. rodentium (5), the mutations caused trunca-
FIGURE 5.Modeling donor substrate specificity of lymphostatin by com-
parison to clostridial toxins. A, alignment of the sequence of lymphostatin
with those LCT residues thought to contribute to specificity for UDP-sugar. B,
PHYRE2 (49) generated model of the GT domain of lymphostatin in complex
with UDP-GlcNac based on Toxin A from C. difficile. Leu667 and Gly669 are
shown in blue and Asp557 and Asp559 in red. C, toxin A from C. difficile in com-
plex with UDP-Glc. Ile382 and Gln384 are shown in blue and Asp285 and Asp287
in red.
FIGURE 6. The putative glycosyltransferase domain of lymphostatin is
not sufficient in isolation to inhibit T cell proliferation. Effect of concen-
tration of rLifA and the purified partial tryptic digestion fragment F1 against
ConA-stimulated peripheral bovine T cells. Data shown are the average of 4
independent donors, done in triplicate. Error bars indicate the S.E. The purity
of the input cells used was 85% in each experiment, as measured by CD3
staining using flow cytometry. Concentrations on the x axis are displayed on
a log scale.
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tion of lymphostatin and subsequent studies with in-frame
deletions suggested the motifs were not essential for intestinal
colonization of cattle by enterohemeorrhagic E. coli O26:H
(4). However, the effect of lymphostatin and motif mutations
on mucosal lymphocytes and induction of adaptive immunity
was not studied and a role for the motifs in pathogenesis there-
fore cannot be excluded. Using purified lymphostatin we have
not observed autocatalytic cleavage via the putative cysteine
protease domain, including under low pH conditions or in the
presence of inositol hexakisphosphate, the co-factor known to
trigger autocatalytic cleavage of LCTs (reviewed in Ref. 56). If
lymphostatin is able to autocatalytically cleave using the CP
motif, either it requires some as yet unidentified co-factor, or
it is not triggered by pH change, and merits further closer
investigation.
Although we have obtained low resolution EM and SAXS
envelopes for lymphostatin, a high resolution structure has
been elusive. A full-length diffracting protein crystal has not yet
been obtained from pilot crystallization trials. Given the behav-
ior of the recombinant protein in solution, high resolution
cryo-EM might be a promising approach to analyze the lym-
phostatin structure. Alternatively, given the data from the par-
tial tryptic digestion, an approach combining crystallization of
predicted domains combined with EM could be used. Circular
dichroism spectroscopy of full-length and theN-terminal puta-
tive glycosyltransferase domain has confirmed the secondary
structure predictions that show theN-terminal third of the pro-
tein to be largely -helical. In addition, the C-terminal third is
very rich in -sheet, both features shared with the LCTs. Inter-
estingly, unlike the LCTs, lymphostatin lacks themultimodular
cell wall/choline-binding repeat that form the receptor-binding
domain (57).
For the first time we report that lymphostatin is able to bind
UDP-GlcNAc, but not UDP-Glc in a manner dependent on a
conserved DXD motif within its predicted glycosyltransferase
domain and that this motif is also required for its activity
against bovine T lymphocytes. Furthermore, inhibition of lym-
phocyte function was not associated with cell lysis as measured
by release of a cytosolic enzyme or effects on the actin cytoskel-
eton, in contrast to LCTs (data not shown) (58, 59). The target
of sugar modification by lymphostatin is unknown, and is likely
to be difficult to identify. For both the LCTs andNleB, therewas
some initial insight into rational candidate acceptor proteins or
signaling pathways prior to their identification.However, this is
not currently the case for lymphostatin. Furthermore, whereas
potential targets of NleB activity were identified by immuno-
precipitation and yeast 2-hybrid approaches, enabling specific
sugar transfer onto putative recombinant targets to be tested
(14, 15), this approach is likely to be technically challenging for
lymphostatin, because of the challenges of cloning the gene in
the vectors required for yeast 2-hybrid screening. Interacting
partners for lymphostatin are presently unknown and a similar
FIGURE 7. Secondary structure analysis. A, far UV CD spectrum of lymphostatin and the major N-terminal fragment F1. B, secondary structure analysis from
CDandpredictions fromprimary sequence indicate that F1 is largely-helical. There is goodagreementbetweenPSIPREDpredictions and secondary structure
analysis of the CD data for full-length lymphostatin. C, secondary structure prediction from primary sequence obtained from PSIPRED.
FIGURE 8. Surface representation of negatively stained rLifA at 23-Å res-
olution. The views are related by a 90 degree rotation around the horizontal
axis. The length of the scale bar equals 5 nm.
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approach may be needed to find its target(s), given the chal-
lenge of detecting addition of labeled GlcNAc to cellular pro-
teins against the large number of endogenous modifications
expected.
Although lymphostatin has recently been demonstrated to
be secreted via Type III secretion (10), the fact that it is active in
an isolated recombinant form, or when produced in E. coli that
lack a type III secretion system, indicates that injection into
cells is not vital for activity against lymphocytes. It is plausible
that it may have both Type III secretion-dependent and -inde-
pendent activities. Our evidence indicates that the full-length
protein is required for inhibition of lymphocyte function as the
isolated F1 fragment encompassing the glycosyltransferase
domain showedno activity, despite being folded and soluble. As
FIGURE 9. SAXS analysis of rLifA. A, the experimental SAXS scattering curve is shown as a logarithmic intensity I (s) versus inverse scattering angle (Å1). The
linear region of the Guinier plot (log I(s) versus s2) is shown as an inset. B, the distance distribution function P(r) with SAXS parameters shown in the inset. Rg,
radius of gyration; theMw (monomer) is the mass calculated from the primary sequence;Mw (SAXS) is the estimated mass calculated from the Porod volume.
C, the refined DAMMIN ab initio beadmodel with indicated dimensions (blue) and its ab initio surface envelope (blue) aligned with the EM density map (gray),
shown in two views related by a 90 degree rotation around the horizontal axis. The SAXS envelope was made transparent with Chimera (44) to visualize the
alignment.
FIGURE 10. Lymphostatin binds UDP-N-acetylglucosamine. Stern-Volmer
plot showing the intrinsic tryptophan fluorescence (340 nm) of lymphostatin,
measured at increasing concentrations of UDP-N-acetyl-glucosamine
(UDP-GlcNAc) and UDP-glucose (UDP-Glc) (Fo/F; where Fo is the fluorescent
intensity before the addition of UDP-sugar). Data points represent themeans
of data in triplicate. Kd for UDP-GlcNAcwas determined to be 120 30M by
fitting the raw fluorescent intensity data to a one-site binding model cor-
rected for collisional quenching (inset).
FIGURE 11. Mutation of the DXD motif of lymphostatin abolishes both
sugar binding and inhibitory activity. A, Stern-Volmer plot showing the
quenching of intrinsic lymphostatin tryptophan fluorescence (340 nm) mea-
sured at increasing concentrations of UDP-GlcNAc and UDP-Glc (Fo/F; where
Fo is the fluorescent intensity before the addition of UDP-sugar). B, effect of
concentrationof rLifA and rLifADTD/AAA against ConA-stimulatedproliferation
of peripheral bovine T cells. Thedata shownare the averageof 3 independent
donors, done in triplicate. Error bars indicate S.E. The calculated ED50 was
0.014 0.0015 ng/ml (rLifA), and 922 270 ng/ml (rLIfADTD/AAA). Concentra-
tions on the x axis are displayed on a log scale.
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with large clostridial toxins the C-terminal domain of lymphos-
tatin may be required for cellular uptake and the GT domain is
unable to act in isolation (60, 61).
Where EPEC and non-O157 EHEC almost invariably express
lymphostatin, in serogroup O157 EHEC strains, lymphostatin
exists as two truncated open reading frames (z4332 and z4333,
encoding proteins identical to residues 1–433 and 435–710 of
full-length lymphostatin) (62, 63). In addition, the pO157 plas-
mid encodes a putative 365-kDa homologue of lymphostatin
named ToxB (L7095), which shares 28% identity and 47%
amino acid similarity to LifA/Efa1 (64, 65). E. coliO157 strains
have a lymphostatin-like activity (3, 15) that has been associ-
ated with the pO157 plasmid (2). Mutation of the truncated
lymphostatin or toxB genes in a Shiga toxin-deficient E. coli
O157 strain did not markedly affect the ability of bacterial
lysates to inhibit bovine lymphocyte proliferation (11). How-
ever, the assay used relied on crude bacterial lysates and is
insensitive compared with the highly purified protein tested
herein, with lysates causing lymphostatin-independent inhibi-
tion of lymphocyte function at higher concentrations (4, 11).
The expression and assay systems described here are likely to be
suitable to assign activities to ToxB and truncated lymphosta-
tin, and indeed a family of homologous cytotoxins described in
pathogenic Chlamydia species (16). Almost two decades after
lymphostatin was originally identified we have demonstrated
that it has sugar-binding potential, that it is a highly potent
inhibitor of T cell proliferation in vitro, and that a DXD motif
predictive of glycosyltransferase function is essential for both
these activities.
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